Association Between Cancer and Sarcoidosis

The purpose of this study is to develop a clinical dataset of sarcoidosis patients with a diagnosis of cancer who are categorized by date of birth, sex, race/ethnicity, clinical information, laboratory and imaging information, time of sarcoidosis onset, cancer type and treatment, time of cancer diagnosis, stage and grade.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcoidosis Cancer Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity, Delayed Immune System Diseases Lymphatic Diseases Lymphoproliferative Disorders Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Miami, Miller School of Medicine

Miami, Florida, 33136, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Sarcoidosis following cancer
Granulomatous reaction must be proven by pathology

Exclusion criteria

. Aged younger than 18 years old.

Treatment and study plan

Primary outcomes

Pathology Proven Sarcoidosis In Patients with Cancer

Time frame: up to 10 years

Number of Participants With Sarcoidosis Events as Assessed by Positive Granulomatous Reaction in the Biopsies of Lung, Mediastinal Lymph Nodes, or Other Organs After Cancer Diagnosis.

Secondary outcomes

Cancer Cytogenetics and Sarcoidosis

Time frame: up to 10 years

Number of Participants With Sarcoidosis Events as Assessed by Cancer Cytogenetic Profiles of Cancer.
Treatment Requirement of Sarcoidosis

Time frame: up to 10 years

Number of Participants With Sarcoidosis Events as Assessed by Requirement of Treatment with Steroid or Other Anti-Sarcoid Medications in Patients with Cancer.

Sponsors and collaborators

Lead sponsor

University of Miami

Other

Registry information

Official study title

Outcome Study of Sarcoidosis: a New Paraneoplastic Syndrome in Patient With Cancer

Important dates

Study start: 2019
Primary completion: 2021
Study completion: 2021
First posted: Feb 18, 2019
Registry last updated: May 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed